The evolution of the HIV/AIDS outbreak among IDUs in Romania

Similar documents
2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Injection of new psychoactive drugs in Romania multi-indicator analysis

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Review on HIV & Associated Infections in Latvia

MEETING REPORT. 1 Introduction and objectives

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Drug consumption among roma population

Most recent data, analyses and feed-back from the 2016 DRID national updates

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

Harm Reduction in Nigeria

Hepatitis prevention in the context of HIV prevention point work in Latvia

Medical Director. and in prison settings in Romania. Ministry of Justice National Administration of Penitentiaries L IŢ

Poland nationalupdate

Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014

Technical Guidance Note for Global Fund HIV Proposals

ROMANIA. Country Progress Report on AIDS Reporting period January 2014 December 2014

Recent trends in drug problems and service provision in Greece

HIV and injecting drug use in the UK

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

NEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA

New trends in harm reduction in Europe: progress made challenges ahead

NSPs in Estonia: current situation and future challenges

INTRAVENOUS INJECTING DRUG USE.

Prevention services for minors in prisons

Signs of success latest national NESI data?

Workshop summary. Exchange on data collection challenges related to new psychoactive substances use. Presentation of the situation

COUNTRY TABLE. MONTENEGRO.

Tajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan

Models of good practice in drug treatment in Europe. Project group

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

The impact of economic recession on drug users and drug treatment

Annual report 2012: the state of the drugs problem in Europe

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Harms and harm reduction workbook. Country X

UNGASS COUNTRY PROGRESS REPORT LATVIA

New EU Health Programme: funding mechanisms for civil society working on HIV and related areas

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

Promoting hepatitis B vaccination

Bangladesh United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific Baseline Assessment Dec 2006

2nd meeting on detecting and responding to outbreaks of HIV among people who inject drugs

HIV/AIDS IN EASTERN EUROPE AND CENTRAL ASIA (EECA) Charles Ssonko HIV/TB/Hepatitis Adviser Medecins Sans Frontieres

ECDC update to the EU Commission Think Tank on HIV/AIDS

Hepatitis and HIV Co-Infection: Situation in Ukraine.

HIV outbreaks among PWID in Europe linking economic, epidemiological and service provision data -

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

Drug situation in Greece

ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD

UNGASS COUNTRY PROGRESS REPORT Republic of Armenia

Access to needle and syringe exchange services in Estonia

Strategies of drug users to avoid infection with hepatitis C

NPS Current situation in Czech Republic. RICHTER Jiri, SANANIM

HIV epidemic around the Baltic Sea

HIV Risk Behaviour in Irish Intravenous Drug Users

Government of Canada Federal AIDS Initiative Milestones

Overview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition

Methods: respondent driven sampling (RDS) was used to recruit PWID

Civil Society Driven Response in Ukraine: A program making a difference and bringing results

FACT SHEET SERBIA (REPUBLIC OF)

Improving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative

Rapporteur report of Session 2: New Trends in TDI clients. Thursday, September 20th 2012, ( Room 106) Chair: Dragica Katalinic

who use drugs in order to assist them in reducing harm while in the cycle of addiction

Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal. Henrique Barros

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

Hepatitis C in Massachusetts Epidemiology and Public Health Response

STRATEGIES FOR MATERNO- FETAL TRANSMISSION OF HIV, HIV AND HBV COINFECTIONS IN CONSTANTA - ROMANIA

HARM REDUCTION IN ASIA. Adeeba Kamarulzaman University of Malaya, Kuala Lumpur

The epidemiology of HIV infection in Greece HIV/AIDS reporting system

IDU Outreach Project. Program Guidelines

[harm-reduction] ROMANIA NEEDS SUPPORT - national drug agency to be moved under police

Integration of collaborative TB/HIV activities with harm reduction services

FIGHTING HIV IN ESTONIA IN 2006 AND Aire Trummal, Liilia Lõhmus, Kristi Rüütel

UNGASS COUNTRY PROGRESS REPORT SINGAPORE

PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS

Trends in injecting drug use in Europe

Results from the NPSinEurope.eu Project 5-Country RAR of New Psychoactive Drugs (NPS)

Bulgaria Bulgaria Drug Report 2018

Prevention of and Immunisation against Hepatitis B and C

Prevention of and Immunisation against Hepatitis B and C

Cambodia Country Advocacy Brief Injecting Drug Use and HIV

Dr Vivian Hope. Health Protection Agency, London. 19 th Annual Conference of the British HIV Association (BHIVA)

Thirty years of harm reduction in the Netherlands HCV elimination ahead?

ECDC and Spanish Ministry of Health workshop:

Minutes of the 18 th HIV/AIDS Think Tank Meeting 5 and 6 June 2012, Luxembourg

SAULIUS ČAPLINSKAS MD, PhD

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

OF THE REPUBLIC OF ARMENIA DECREE. 316 of 1 April 2002 Yerevan

Mid-term Review of the UNGASS Declaration of. Commitment on HIV/AIDS. Ireland 2006

Country_name (MONGOLIA)

Bangladesh Country Advocacy Brief Injecting Drug Use and HIV

Version for the Silent Procedure 29 April Agenda item January Hepatitis

National HIV Behavioral Surveillance Portland, Oregon

First results collected by Argos, DCR in Strasbourg opened in november 2016

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

Session I. Update on synthetic cathinones injection in Hungary

GLOBAL AIDS RESPONSE PROGRESS REPORTING (GARPR) 2014 COUNTRY PROGRESS REPORT SINGAPORE

Republic of Bulgaria. Reporting period: January 2003 December National Committee on Prevention of AIDS and STDs at the Council of Ministers

Transcription:

The evolution of the HIV/AIDS outbreak among IDUs in Romania Romanian National Antidrug Agency Romanian National Focal Point on Drugs Andrei Botescu * Lisbon, 12 th October 2012

HIV outbreak among IDU s Description of the outbreak In November 2011, a strong increase of newly diagnosed HIV infections among IDUs during 2011 was reported While reporting one to seven new HIV+ IDU s cases annually from 2007 to 2009, HIV infections amongidusincreasedto14casesin2010andto131in2011followedby237in2012and133inthe first six months of 2013. Cases reported in the first six months of 2013 were mostly from Bucharest and surroundings (113 outof133cases),mostlymales(102outof133cases),andbetween25and34yearsold. Routine monitoring within the drug related treatment system performed by the Romanian National Focal Point (RNFP) shows that HIV started to increase among IDUs since 2009 reaching 11,6% in 2011, more than 10 times over the figure registered in 2008 (1,1%). In 2012 we have reached a 24,9% HIV prevalence among IDU s. In the first six months of 2013 the HIV prevalence is slightly increasing at 25,6. 30 20 10 0 24,9 4,1 11,6 3,3 1,1 1,6 1,1 0 1,4 2004 2005 2006 2007 2008 2009 2010 2011 2012

6 months evolution HIV, HBV, HCV routine monitoring 90 80 82,6 77,9 70 70,2 60 50 40 30 20 36 32,6 23,2 25,6 17,2 16,6 HIV HVB HVC 10 0 primele 6 luni 2012 ultimele 6 luni 2012 primele6 luni 2013 HIV 36 23,2 25,6 HVB 32,6 17,2 16,6 HVC 82,6 77,9 70,2

Newly notified cases (HIV among IDU s) 250 231 200 177 150 100 151 98 133 133 verticala msm idu heterosexuala necunoscuta 50 37 43 44 0 18 19 9 9 710 primele 6 luni 2012 ultimele 6 luni 2012 primele6 luni 2013

Epidemiological update

Behavioural Surveillance Survey (RDS sampling 2012 Bucharest) Fresh data from the 2012 BSS among IDUs in Bucharest shows significant changes in HIV prevalence among IDUs, with 53,3% of IDUs in the sample being HIV positive. 58,5% prevalence for the respondents less than 25 years old. NSP users 71.4% prevalence vs heroin users 39.3 Changes in drug use patterns from 2009. In BSS 2009 97% of respondents reported heroin as the main drug of injection while in BSS 2010 67% reported heroin and 31% reported amphetamine-type stimulants, mostly synthetic cathinones, as the main drug of injection. In 2012 BSS significant changes are seen in drug use patterns. The main drugs of injection were NPS (the new amphetamine type stimulants) for 49.4% of the IDUs. The HCV rate among IDUs is 79.3%. Frequentinjection mean-4.27times aday 20,1 declared sharing needles The sample size was 417 and all respondents were recruited using RDS (respondent driven sampling). Source: Carusel 2012 BSS among IDUs in Bucharest crude data - unpublished

HIV outbreak risk factors The switch of injecting drug users to the new stimulants - NPS from opiates determined higher frequency, injecting- 6-10 times/ day comparing with 3-5times/dayforopiates. Previous HCV positive status could be considered a facilitator for HIV infection, and is an indicator for injecting risks, including the sharing of injecting equipment, unprotected sexual contacts, high frequency injecting, etc. Moreover, in Romania HCV therapy is underfinanced. ART has a good provision among general population. However many IDUs have problems registering to treatment as they do not possess legal ID papers, health insurance, or a stable home. Low service provision. The total number of cases OST provision in 2012 is 1030 (including new and old cases) in aprox 700 OST slots available and 1 074 394 syringes distributed to 4488 clients comparable with 2011 but two times less than 2008-2009. In2013wedonothaveconfirmeddatabutthesignalsarealarming. Also the lack of services specialised on stimulant addiction treatment leave a large IDUS population without treatment alternative. The recent decrease in the number of syringes provided through needle and syringe programmes.

Stepstakenuntilnow Response to the HIV outbreak among IDUs has been limited due to lack of finances and lack of an approved national HIV prevention strategy. Recently the HIV prevention strategy 2013-2015 was approved but the interventions are still waited. A new needle exchange centrewas opened in 2012 by Carusel NGO supported by NAA The NAA has purchased 942.500 syringes which were distributed through outreach services. ARAS through an EU financed GRANT was able to buy for 2012 1,000,000 syringes, thus theoretically to equal the number of syringes provided in 2009.

Conclusions The HIV/AIDS HIV spread among IDU s in Romania need to be followed closely both by Romanian authorities and the European and Global public health entities. Both the Global Found Programme and UNODC programme have had a crucial role in creating a national network of harm reduction services in Romania, focused mostly on Bucharest, the city with most of the problematic drug use. NAA and the Ministry of Health have built up a drug treatment network which is competitive although sub financed. However these efforts were not enough to safeguard the IDU population from exposure to HIV/AIDS and other infectious diseases like HVC. Since 2011 the cases of HIV/AIDS+ among IDU s have been steadily growing and the peak of this trend is far from being foreseen. This may cause soon a very dangerous public health problem as HIV+ can be spread rapidly to other risk categories like CSW or MSM or to the close peers of the infected persons.

Thank you! 10